Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Sicherheits- und Wirksamkeitsbewertung des iNstroke 4F Thromboaspirationskatheters bei Patienten mit akutem ischämischem Schlaganfall aufgrund primärer distaler Medium-Vessel-Okklusionen (DMVO) (4-NiVO)

3. November 2026 aktualisiert von: iVascular S.L.U.

Prospektive, einarmige, multizentrische Studie zur Bewertung der Wirksamkeit und Sicherheit des iNstroke 4F Thromboaspirationskatheters bei Patienten mit akutem ischämischem Schlaganfall aufgrund primärer distaler Medium-Vessel-Okklusionen (DMVO).

Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Intervention / Behandlung

Detaillierte Beschreibung

This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.

In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.

Studientyp

Interventionell

Einschreibung (Geschätzt)

57

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Bonn, Deutschland
        • Universitätsklinikum Bonn
      • Kiel, Deutschland
        • Universitätsklinikum Schleswig-Holstein
      • Marburg, Deutschland
        • Klinikum Marburg
      • Nuremberg, Deutschland
        • Klinikum Nürnberg
      • Recklinghausen, Deutschland
        • Knappschaftskrankenhaus Recklinghausen
      • Barcelona, Spanien
        • Hospital Universitario Vall d'Hebron
      • Madrid, Spanien
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien
        • Hospital Universitario La Paz
      • Madrid, Spanien
        • Hospital Universitario de Getafe
      • Murcia, Spanien
        • Hospital Clínico Universitario Virgen de Arrixaca
      • Budapest, Ungarn
        • Semmelweis University Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Subjects aged ≥ 18 years.
  • Subjects with symptom onset up to 24 hours.
  • Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
  • Baseline NIHSS score ≥5 assessed before the procedure.
  • Pre-stroke mRS score ≤ 2.
  • Subjects with an ASPECTS score ≥ 6.
  • Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).

Exclusion Criteria:

  • Subjects aged < 18.
  • Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
  • Baseline NIHSS score <5 assessed before the procedure.
  • Pre-stroke mRS score >2.
  • Subjects with an ASPECTS score <6.
  • Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
  • Severe allergy to contrast media.
  • Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
  • Medical history of thrombocytopenia (Platelets <100,000).
  • Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
  • Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
  • Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
  • Subjects participating in a clinical trial at the moment of the inclusion.
  • Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Thromboaspiration using iNstroke 4F aspiration catheter

No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose.

Patients to undergo thromboaspiration with iNstroke 4F

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recanalization Endpoint
Zeitfenster: Intra-procedure

Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR.

Intra-procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy

Intra-procedure
Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy.

Intra-procedure
Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR.

Intra-procedure
Recanalization Endpoint
Zeitfenster: Intra-procedure

Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy.

Intra-procedure
Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter.

Intra-procedure
Clinical Endpoint
Zeitfenster: 90 day

Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit.

90 day
Safety Endpoint
Zeitfenster: 24 (-8/+12) hours

Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT).

Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration.

24 (-8/+12) hours
Safety Endpoint
Zeitfenster: Intra-procedure

Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure.

Intra-procedure
Safety Endpoint
Zeitfenster: Intra-procedure

Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure.

Intra-procedure
Safety Endpoint
Zeitfenster: During hospital admission

Inhospital mortality rate related to the procedure during hospital admission.

During hospital admission
Safety Endpoint
Zeitfenster: 90 days (±14 days) after the procedure.

Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure.

90 days (±14 days) after the procedure.
Safety Endpoint
Zeitfenster: Intra-procedure

Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel.

Intra-procedure

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Exploratory Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy.

Intra-procedure
Exploratory Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy.

Intra-procedure
Exploratory Recanalization Endpoint
Zeitfenster: Intra-procedure

Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion.

Intra-procedure
Exploratory Recanalization Endpoint
Zeitfenster: Intra-procedure

Number of passes with iNstroke 4F aspiration catheter until recanalization.

Intra-procedure
Exploratory Recanalization Endpoint
Zeitfenster: Intra-procedure

Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score).

Intra-procedure
Exploratory Clinical Endpoint
Zeitfenster: 24 (-8/+12) hours post-procedure.

Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure.

24 (-8/+12) hours post-procedure.
Exploratory Clinical Endpoint
Zeitfenster: First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.

Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first.

First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
Exploratory Clinical Endpoint
Zeitfenster: 24 (-8/+12) hours.

Median of NIHSS score at 24 (-8/+12) hours.

24 (-8/+12) hours.
Exploratory Clinical Endpoint
Zeitfenster: 3 days (±24 hours) post procedure

Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first.

3 days (±24 hours) post procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

27. November 2025

Primärer Abschluss (Geschätzt)

1. November 2026

Studienabschluss (Geschätzt)

1. November 2026

Studienanmeldedaten

Zuerst eingereicht

9. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Januar 2026

Zuerst gepostet (Tatsächlich)

22. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren